Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

HR 756 is a new cephalosporin derivative suitable for parenteral use. The compound possesses an unusally broad spectrum of antibacterial activity especially against gram-negative bacteria. Besides Escherichia coli, Salmonella, Klebsiella, indole-negative Proteae and other species also indol-positive Proteae, Serratia marcescens, Enterobacter and many Pseudomonas aeruginosa strains are inhibited by this compound. HR 756 is stable to most of the beta-lactamases produced by gram-negative organisms. Tests on different infection models also provided evidence of the high efficacy of HR 756 in vivo.